Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Filings today ..

<< Previous

Bullboard Posts

Next >>

Post by Mole101on Jan 15, 2021 8:19pm

342 Views

Post# 32312108

Filings today ..

Filings by transaction date

Jan 11, 2021 (filed on Jan 15, 2021)

Insider Name:

Wilson, Alain

Ownership Type:

Control or Direction

Securities:

Restricted Share Units

Nature of Transaction:

56 - Grant of rights

# or value acquired/disposed of:

124,700

Price:

--
Jan 11, 2021 (filed on Jan 15, 2021)

Insider Name:

Wallace, John Lawrence

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

56 - Grant of rights

# or value acquired/disposed of:

484,200

Price:

--
Jan 11, 2021 (filed on Jan 15, 2021)

Insider Name:

Vaughan, David James

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

56 - Grant of rights

# or value acquired/disposed of:

102,700

Price:

--
Jan 11, 2021 (filed on Jan 15, 2021)

Insider Name:

Stauffer, Joseph

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

56 - Grant of rights

# or value acquired/disposed of:

70,000

Price:

--
Jan 11, 2021 (filed on Jan 15, 2021)

Insider Name:

Macnee, Walter Minnes

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

56 - Grant of rights

# or value acquired/disposed of:

40,000

Price:

--
Jan 11, 2021 (filed on Jan 15, 2021)

Insider Name:

Legault, Daniel Marcel

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

56 - Grant of rights

# or value acquired/disposed of:

513,200

Price:

--
Jan 11, 2021 (filed on Jan 15, 2021)

Insider Name:

Khouri, Amal

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

56 - Grant of rights

# or value acquired/disposed of:

40,000

Price:

--
Jan 11, 2021 (filed on Jan 15, 2021)

Insider Name:

Flower, Roderick John

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

56 - Grant of rights

# or value acquired/disposed of:

40,000

Price:

--
Jan 11, 2021 (filed on Jan 15, 2021)

Insider Name:

Curtis, Scott Wilson

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

56 - Grant of rights

# or value acquired/disposed of:

102,700

Price:

--
Jan 11, 2021 (filed on Jan 15, 2021)

Insider Name:

Batal, Rami

Ownership Type:

Direct Ownership

Securities:

Restricted Share Units

Nature of Transaction:

56 - Grant of rights

# or value acquired/disposed of:

64,500